Cidofovir, a new agent with potent anti-herpesvirus activity

Antiviral Chemistry and Chemotherapy

Volumn 7, Issue 3, 1996, Pages 115-127

  Hitchcock, M J M ^a   Jaffe, H S ^a   Martin, J C ^a   Stagg, R J ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CELL ENZYME; CIDOFOVIR; CIDOFOVIR DIPHOSPHATE; DNA POLYMERASE; FOSCARNET; GANCICLOVIR; NEW DRUG; UNCLASSIFIED DRUG; VIRUS ENZYME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CROSS RESISTANCE; CYTOMEGALOVIRUS INFECTION; DNA VIRUS; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; DRUG UPTAKE; GLUCOSURIA; HERPES VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEINURIA; RETINITIS; REVIEW; VIRUS MUTATION;

EID: 0029914381     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029600700301     Document Type: Review

References (70)

1. Aduma, P., Connelly, M. C., Srinivas, R. V., and Fridland, A. (1995) Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 47: 816-822.
2. Andrei, G., Snoeck, R., Schols, D., Goubau, P., Desmyter, J., and De Clercq, E. (1991) Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis 10: 1026-1033.
3. Biron, K.K., Stanat, S.C., Sorrell, J.B., Fyfe, J.A., Keller, P.M., Lambe, C.U., and Nelson, D.J. (1985) Metabolic activation of the nucleoside analog 9- ([2-hydroxy-1-(hydroxymethyl)-ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci USA 82: 2473-2477.
4. Bronson, J.J., Ghazzouli, I., Hitchcock, M.J.M., Webb, R.R., and Martin, J.C. (1989) Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem 32: 1457-1463.
5. Bronson, J.J., Ferrara, L.M., Hitchcock, M.J.M., Ho, H., Woods, K.L., Ghazzouli, I., Kern, E.R., Soike, K.F., and Martin, J.C. (1990) (S)-1-(3-hydroxy-2-(phosphonyl-methoxy)propyl)-cytosine (HPMPC): A potent anti-herpesvirus agent. In Immunobiology and prophylaxis of human herpesvirus infections. Lopez, C. et al. (eds). New York:Plenum Press, pp. 277-283
6. Cherrington, J.M., Allen, S.J.W., and Chen, M.S. (1994) Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxy-propyl) cytosine, zalcitabineTP, zidovudineTP, and FIAUTP with human DNA polymerases β and γ. Biochem Pharmacol 48:1986-1988.
7. Cherrington, J.M., Allen, S.J.W., Mulato, A.S., Miner, R., Drew, W.L., and Chen, M.S. (1995) Sensitivities of human cytomegalovirus (HCMV) clinical isolates to cidofovir. Antiviral Res 26: A319.
8. Cherrington, J.M., Miner, R., Lalezari, J., Hitchcock, M.J.M., and Drew, W.L. (1996) Susceptibility of human cytomegalovirus (HCMV) to cidofovir is unchanged after limited exposure in vivo to various clinical regimens of drug. J Infect Dis (in press).
9. Chou, S., Erice, A., Jordan, M.C., Vercellotti, G.M., Michels, K.R., Talarico, C.L., Stanat, S.C., and Biron, K.K. (1995) Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 171: 576-583.
10. Cihlar, T., Votruba, I., Horska, K., and Liboska, R. (1992) Metabolism of 1-(S)-(3-hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 57: 661-672.
11. Connelly, M.C., Robbins, B.L., and Fridland, A. (1993) Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem Pharmacol 46: 1053-1057.
12. Cundy, K.C., Li, Z.-H., and Lee, W.A. (1994) Effect of concomitant probenecid on the tissue distribution and urinary excretion of HPMPC in preclinical models. Pharm Res 11 (Suppl.): S-449.
13. Cundy, K.C., Petty, B.G., Flaherty, J., Fisher, P.E., Polis, M.A., Wachsman, M., Lietman, P.S., Lalezari, J.P., Hitchcock, M.J.M., and Jaffe, H.S. (1995) Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 39: 1247-1252.
14. Cundy, K.C., Li, Z., Hitchcock, M.J.M., and Lee, W.L. (1996) Pharmacokinetics of cidofovir in monkeys: evidence for a prolonged elimination phase represents phosphorylated drug. Drug Metab Dispos (in press).
15. De Clercq, E., Holy, A., Rosenberg, I., Sakuma, T., Baizarini, J., and Maudgal, P.C. (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323: 464-467.
16. De Clercq, E., Sakuma, T., Baba, M., Pauwels, R., Balzarini, J., Rosenberg, I., and Holy, A. (1987) Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 8: 261-272.
17. Erice, A., Chou, S., Biron, K.K., Stanat, S.C., Balfour, H.H., and Jordan, M.C. (1989) Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients. New Eng J Med 320: 289-293.
18. Flores-Aguilar, M., Huang, J., Wiley, C.A., De Clercq, E., Vuong, C., Bergeron-Lynn. G., Chandler, B., Munguia, D., and Freeman, W.R. (1994) Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine. J Infect Dis 169: 642-647.
19. Gordon, Y.J., Romanowski, E., Araullo-Cruz, T., and De Clercq, E. (1992) Pretreatment with topical 0.1% (S)-1- (3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model. Cornea 11: 529-533.
20. Gordon, V.J., Romanowski, E., and Araullo-Cruz, T. (1994) Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthal Vis Sci 35: 4135-4143.
21. Heijtink, R.A., Kruining, J., De Wilde, G.A., Balzarini, J , De Clercq, E., and Schalm, S.W. (1994) Inhibitory effects of acyclic nucleoside phosphonates on Human Hepatitis B Virus and Duck Hepatitis B Virus infections in tissue culture. Antimicrob Agents Chemother 38: 2180-2182.
22. Hitchcock, M.J.M., Lacy, S.A., Lindsey, J.R., and Kern, E.R. (1995) The cyclic congener of cidofovir has reduced nephrotoxicity in three species. Antiviral Res 26: A358.
23. Ho, H.-T., Woods, K.L, Bronson, J.J., De Boeck, H., Martin, J.C., and Hitchcock, M.J.M. (1992) Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 41: 197-202.
24. Holy, A., Votruba, I., Merta, A., Cerny, J., Vesely, J., Vlach, J., Sediva, K., Rosenberg, I., Otmar, M., Hrebabecky, H., Travnicek, M., Vonka, V., Snoeck, R., and De Clercq, E. (1990) Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res 13: 295-312.
25. Kern, E.R. (1991) Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Transplant Proc 23: 152-155.
26. Kern, E.R., Palmer, J., Hartline, C., and Vogt, P.E. (1995) Comparison of efficacy and toxicity of HPMPC and cyclic HPMPC in animal models for severe herpesvirus infections. Antiviral Res 26: A329, Abstract 195.
27. Lalezari, J.P., Drew, W.L., Glutzer, E., Miner, D., Safrin, S., Owen, W.F., Davidson, J.M., Fisher P.E., and Jaffe, H.S. (1994) Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 170: 570-572.
28. Lalezari, J.P., Drew, W.L., Glutzer, E., James, C., Miner, D., Flaherty, J., Fisher, P.E., Cundy, K., Hannigan, J., Martin, J.C., and Jaffe, H.S (1995) (S)-1-[3-Hydroxy-2-(Phosphonylmethoxy)propyl]cytosine (cidofovir): results of a Phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 171: 788-796.
29. Li, S.B., Yang, Z.H., Feng, J.S., Fong, C.K.Y., Lucia, H.L., and Hsiung, G.D. (1990) Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res 13: 237-252.
30. Lin, J., De Clercq. E., and Pagano, J.S. (1991) Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, on Epstein-Barr virus replication. Antimicrob Agents Chemother 35: 2440-2443.
31. Littler, D., Stuart, A.D., and Chee, M.S. (1992) Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358: 160-162.
32. Lurain, N.S., Thompson, K.D., Holmes, E.W., and Read, G.S. (1992) Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 66: 7146-7152.
33. Lurain, N.S., Spafford, L.E., and Thompson, K.D. (1994) Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 68: 4427-4431.
34. Martin, J.C., and Hitc̀hcock, M.J.M. (1991) Phosphonomethylether compounds as antiviral agents. Transplant Proc 23: 156-158.
35. Mendel, D.B., Barkhimer, D.B., and Chen, M.S. (1995a) Biochemical basis for increased susceptibility to cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity. Antimicrob Agents Chemother 39: 2120-2122.
36. Mendel, D.B., Barkhimer, D.B., Kern, E.R., and Chen, M.S. (1995b) Isolation and initial characterization of a herpes simplex virus type 2 (HSV-2) strain with decreased sensitivity to cidofovir. Antiviral Res 26: A312.
37. Neyts, J., Snoeck, R., Schols, D., Balzarini, J., and De Clercq, E. (1990) Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1, 3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 179: 41-50.
38. Neyts, J., Snoeck, R., Balzarini, J., and De Clercq, E. (1991a) Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine (HPMPC) in vitro. Antiviral Res 16: 41-52.
39. Neyts, J., Snoeck, R., Schols, D., Himpens, B., and De Clercq, E. (1991b) Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anticytomegalovirus agents. J Virol Methods 35: 27-38.
40. Neyts, J., Balzarini, J., Naesens, L., and De Clercq, E. (1992) Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and ganciclovir for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice. J Med Virol 37: 67-71.
41. Otova, B., Votruba, I., and Holy, A. (1992) Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect. Acta Virol 36: 313-319.
42. Palestine, A.G., Polis, M.A., DeSmet M.D. et al. (1991) A randomized, controlled trial of foscamet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 115: 665-673.
43. Polis, M.A. (1992) Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 5: S3-S10.
44. Polis, M.A., Spooner, K.M., Baird, B.F., Manischewitz, J.F., Jaffe, H.S., Fisher, P.E., Falloon, J., Davey, R.T., Kovacs, J.A., Walker, R.E., Whitcup, S.M., Nussenblatt, R.B., Lane, H.C., and Masur, H. (1995) Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 39: 882-686.
45. Reid, R., Mar, E.-C., Huang, E.-S., and Topal, M.D. (1988) Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α and human β polymerases. J Biol Chem 263: 3898-3904.
46. Reyman, D., Naesens, L., Balzarini, J., Holy, A., and De Clercq, E. (1995) Antiviral activity of selected nucleoside analogues against human herpes virus type 6. Antiviral Res 26: A326.
47. Shigeta, S., Konno, K., Baba, M., Yokota, T., and De Clercq, E. (1991) Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J Infect Dis 163: 270-275.
48. Smee, D.F., Morris, J.B., Leonhardt, J.A., Mead, J.R., Holy, A., and Sidwell, R.W. (1992) Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother 36: 1837-1842.
49. Smee, D.F., Sugiyama, S.T., and Reist, E.J. (1994) Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrob Agents Chemother 38: 2165-2168.
50. Smee, D.F., Barnett, B.B., Sidwell, R.W., Reist, E.J., and Holy, A. (1995) Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus. Antiviral Res 26: 1-9.
51. Snoeck, R., Sakuma, T., De Clercq, E., Rosenberg, I., and Holy A. (1988) (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)-cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 32: 1839-1844.
52. Snoeck, R., Schols, D., Andrei, G., Neyts, J., and De Clercq, E. (1991) Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. Antiviral Res 16: 1-9.
53. Snoeck, R., Andrei, G., Gerard, M., Silverman, A., Hedderman, A., Balzarini, J., Sadzot-Delvaux, C., Tricot, G., Clumeck, N., and De Clercq, E. (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 18: 570-578.
54. Snoeck, R., Andrei, G., and De Clercq, E. (1995a) Human cytomegalovirus (HCMV) strains selected under selective pressure of phosphonoformate (PFA) are resistant for both PFA and phosphonylmethoxyethyl (PME) derivatives in vitro. Antiviral Res 26: A320.
55. Snoeck, R., Van Ranst, M., Andrei, G., De Clercq, E., De Wit, S., Poncin, M., and Clumeck, N. (1995b) Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. New Engl J Med 333: 943-944.
56. Soike, K.F., Huang, J.-L. Zhang, J.-Y., Bohm, R., Hitchcock. M.J.M., and Martin, J.C. (1991) Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on Simian Varicella Infection in monkeys. Antiviral Res 16: 17-28.
57. Spector, S.A., Weingeist, T., Pollard, R.B., Dieterich, D.T., Samo, T., Benson, C.A., Busch, D.F., Freeman, W.R., Montague, P., Kaplan, H.J., Kellerman, L., Crager, M., De Armond, B., Buhles, W., Feinberg, J., AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. (1993) A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 168: 557-563.
58. Stals, F.S., De Clercq, E., and Bruggeman, C.A. (1991) Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1, 3-dihydroxy-2-propoxymethyl) guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicrob Agents Chemother 35: 2262-2266.
59. Stals, P.S., Zeytinoglu, A., Havenith, M., De Clercq, E., and Bruggeman, C.A. (1993a) Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. Antimicrob Agents Chemother 37: 218-223.
60. Stals, F.S., Zeytinoglu, A., Havenith, M., De Clercq, E., and Bruggeman, C.A. (1993b) Comparative effect of (S)-1- (3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9- (1, 3-dihydroxy-2-propoxymethyl)guanine treatment on cytomegalovirus-induced interstitial pneumonitis in allogeneic bone marrow transplant recipient rats. Transplant Proc 25: 1248-1249.
61. Stanat, S.C., Reardon, J.E., Erice, A., Jordan, M.C., Drew, W.L., and Biron, K.K. (1991) Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 35: 2191-2197.
62. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. (1994) Foscarnet-ganciclovir cytomegalovirus retinitis trial. 4. Visual outcomes. Ophthalmology 101: 1250-1261.
63. Sullivan, V., and Coen, D.M. (1991) Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 164: 781-784.
64. Sullivan, V., Talarico, C.L., Stanat, S.C., Davis, M., Coen, D.M., and Biron, K.K. (1992) A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358: 162-164.
65. Sullivan, V., Biron, K.K., Talarico, C., Stanat, S.C., Davis, M., POZZI, L.M., and Coen, D.M. (1993) A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 37: 19-25.
66. Tatarowicz, W.A., Lurain, N.S., and Thompson, K.D. (1992) A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 166: 904-907.
67. Van Cutsem, E., Snoeck, R., Van Ranst, M., Fiten, P., Opdenakker, G., Geboes, K., Janssens, J., Rutgeerts, P., Vantrappen, G., and De Clercq, E. (1994) Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol 45: 230-235.
68. Wachsman, M., Petty, B.G., Cundy, K.C., Jaffe, H.S., Fisher, P.E., Pastelak, A., and Lietman, P.S. (1996) Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in HIV-infected subjects. Antiviral Res (in press).
69. Xiong, X., Smith, J.L., and Chen, M.S. (1995) The consequence of incorporation of (S)-1- (3-hydroxy-2-phosphonylmethoxypropyl)cytosine by human cytomegalovirus DNA polymerase on DNA elongation. Antiviral Res 26: A321.
70. Yang, H., and Datema, R. (1991) Prolonged and potent therapeutic and prophylactic effects of (S)-1-[ (3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against Herpes Simplex Virus Type 2 infections in mice. Antimicrob Agents Chemother 35: 1596-1600.